NewsBenzingaHeron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement Benzinga 2026.09.29 21:07 (GMT+0) Open on Benzinga Other news Earnings Preview: What to Expect From Mosaic’s Report Gartner’s Q3 2026 Earnings: What to Expect Global Payments’ Quarterly Earnings Preview: What You Need to Know Earnings Preview: What to Expect From Assurant Report What a New Nvidia-Backed AI Platform Means for Honeywell Stock What You Need to Know Ahead of Yum! Brands' Earnings Release
